XSUITE
7.8.2024 15:48:31 CEST | Business Wire | Press release
xSuite Nordic, a subsidiary of software manufacturer xSuite Group, invites customers and prospects to its roadshow in Copenhagen/Valby (5.9.24) and Horsens (12.9.24). Participants will be taken on a journey that brings them closer to SAP S/4HANA, Clean Core and the SAP Business Technology Platform (BTP). They will learn how xSuite solutions can be used to set up future-proof P2P processes for SAP S/4HANA. xSuite will also showcase how to combine automation and intuitive workflows for incoming invoice processing based on the clean core principle.
SAP user companies have a lot on their plate these days: Prepare for the migration to S/4HANA, push ahead process digitization and improvement, and move to the cloud. At the roadshow, Bo Bærentsen, Senior Business Consultant, and Michael Francker Christensen, Solution Architect (both from xSuite), will present how xSuite supports organizations on their journey to a clean core, with a focus on P2P processes and SAP S/4HANA.
Maiken Borup-Mikkelsen, People Lead & Director DC, SAP at Deloitte Denmark, talks about the future of work: What does the future of work look like in the SAP context? In Valby, Ólafur Harðarson, IT Application Manager from Síminn Telecommunications Reykjavik Island, will introduce Síminn’s change story “From a lot of SAP to better SAP”.
In Horsens, Charlotte Uhrskov Johansen, Project Lead & Manager Future Finance at Bestseller, will present how the company migrated to S/4HANA globally in order to achieve more automation and efficiency in financial processes. Bestseller is implementing SAP Fiori for all financial processes in the S/4HANA Private Cloud.
Martin Lundsteen, Managing Director of xSuite Nordic, will guide participants through the series of presentations on both dates. Afterwards, xSuite invites guests to a get-together from 12 noon to 1 p.m.
Event information:
Duration of both events: 9:30 a.m. – 1:00 p.m.
The presentations will be given in Danish at both locations.
05.9.24, Copenhagen/Valby
Transformerstationen
Gl. Køge Landevej 18
2500 Valby, Denmark
12.9.24, Horsens
Jorgensens Hotel
Søndergade 17
8700 Horsens, Denmark
More information and registration: https://news.xsuite.com/en/international-roadshow-2024
About xSuite
With offices in Europe, Asia, and the U.S., as well as ample experience across industries and multiple SAP solutions, xSuite is a top innovator in optimizing SAP-based P2P workflows, providing software and implementing solutions for over 1,300 clients. The company has become a trusted partner in modernizing AP systems and automating manual, paper-based processes.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240807495174/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom